SCHEMBL18396809

SCHEMBL18396809

Cc1ccc(S(=O)(=O)OCC2CCC(COS(=O)(=O)c3ccc(C)cc3)N2C(=O)O)cc1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 2/20 0.45
CYP2D6 P10635 2/20 0.44
ALDH1A1 P00352 5/20 0.42
CYP1A2 P05177 1/20 0.42
CTDSP1 Q9GZU7 1/20 0.40
SIRT5 Q9NXA8 1/20 0.40
MEN1 O00255 1/20 0.40
CYP2C9 P11712 1/20 0.40
KMT2A Q03164 1/20 0.40
ENPP3 O14638 2/20 0.40
ENPP1 P22413 2/20 0.40
ENPP2 Q13822 2/20 0.40
TAS2R14 Q9NYV8 1/20 0.39
KDM4E B2RXH2 1/20 0.39
LMNA P02545 1/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2463859 0.92 STAT3 (0.41) STAT3CYP2D6ALDH1A1CYP1A2CTDSP1
SCHEMBL23245584 0.86 STAT3 (0.43) STAT3CYP2D6ALDH1A1CYP1A2CTDSP1
SCHEMBL26907053 0.83 CYP2D6 (0.45) STAT3CYP2D6ALDH1A1CYP1A2CTDSP1
SCHEMBL3834098 0.83 CYP2D6 (0.45) STAT3CYP2D6ALDH1A1CYP1A2CTDSP1
SCHEMBL25418266 0.83 CYP2D6 (0.45) STAT3CYP2D6ALDH1A1CYP1A2CTDSP1
SCHEMBL30586531 0.82 MMP13 (0.46) STAT3CYP2D6ALDH1A1MEN1KMT2A
SCHEMBL6047460 0.82 STS (0.43) STAT3CYP2D6ALDH1A1CYP1A2MEN1
SCHEMBL30998760 0.82 STS (0.43) STAT3CYP2D6ALDH1A1CYP1A2MEN1
SCHEMBL20956523 0.82 ALDH1A1 (0.41) STAT3CYP2D6ALDH1A1CYP1A2MEN1
SCHEMBL20956512 0.82 DPP4 (0.43) STAT3CYP2D6ALDH1A1CYP1A2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11964949-B2 Substituted phenyloxazolidinones for antimicrobial therapy THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) 2024-04-23 US disclosed
WO-2023192801-A1 SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS NIKANG THERAPEUTICS, INC. (US) 2023-10-05 WO disclosed
EP-3932917-A2 SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY The Global Alliance for TB Drug Development, Inc. (US) 2022-01-05 EP disclosed
US-20200148651-A1 SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) 2020-05-14 US disclosed
US-10550092-B2 Substituted phenyloxazolidinones for antimicrobial therapy THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) 2020-02-04 US disclosed
US-20180179168-A1 SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. 2018-06-28 US disclosed
EP-3307268-A1 SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY The Global Alliance for TB Drug Development Inc. (US) 2018-04-18 EP disclosed
WO-2017015106-A1 SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) 2017-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11964949-B2 Substituted phenyloxazolidinones for antimicrobial therapy THPO, TBCD, OXA1L STAT3 1059/4885CYP2D6 1393/4885ALDH1A1 1310/4885
US-20180179168-A1 SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY THPO, TBCD, OXA1L STAT3 1059/4885CYP2D6 1393/4885ALDH1A1 1310/4885
US-20200148651-A1 SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY THPO, TBCD, OXA1L STAT3 1059/4885CYP2D6 1393/4885ALDH1A1 1310/4885
US-10550092-B2 Substituted phenyloxazolidinones for antimicrobial therapy THPO, TBCD, OXA1L STAT3 1059/4885CYP2D6 1393/4885ALDH1A1 1310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.